Consider Olanzapine for chemotherapy-induced nausea/vomiting

Mark Lewis posted on X/Twitter about a recent paper by Jyoti Bajpai et al., commenting:

“I am once again asking you to consider prescribing olanzapine for patients experiencing chemotherapy-induced nausea/vomiting

* it’s an effective antiemetic
* it can enable better sleep (but less daytime somnolence at 2.5mg vs. 10mg)
* it can boost mood.”

Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial

Journal: The Lancet Oncology

Author:  Jyoti Bajpai, Venkatesh Kapu, Sushmita Rath, Sravan Kumar, Anbarasan Sekar, Priyanka Patil, Altaf Siddiqui, Srikanth Anne, Akash Pawar, Sujay Srinivas, Prabhat Bhargava, Seema Gulia, Vanita Noronha, Amit Joshi, Kumar Prabhash, Shripad Banavali, Rajiv Sarin, Rajendra Badwe, Sudeep Gupta

Source: Mark Lewis/X

Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent & young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.